BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 19372091)

  • 1. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
    Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
    Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy.
    Messalli G; Imbriaco M; Avitabile G; Russo R; Iodice D; Spinelli L; Dellegrottaglie S; Cademartiri F; Salvatore M; Pisani A
    Radiol Med; 2012 Feb; 117(1):19-28. PubMed ID: 21744250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
    Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
    Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
    Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
    Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
    Kampmann C; Linhart A; Devereux RB; Schiffmann R
    Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy improves cardiac features and severity of Fabry disease.
    Motwani M; Banypersad S; Woolfson P; Waldek S
    Mol Genet Metab; 2012 Sep; 107(1-2):197-202. PubMed ID: 22704481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
    Spinelli L; Pisani A; Sabbatini M; Petretta M; Andreucci MV; Procaccini D; Lo Surdo N; Federico S; Cianciaruso B
    Clin Genet; 2004 Aug; 66(2):158-65. PubMed ID: 15253767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
    Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
    Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.
    Kovacevic-Preradovic T; Zuber M; Attenhofer Jost CH; Widmer U; Seifert B; Schulthess G; Fischer A; Jenni R
    Eur J Echocardiogr; 2008 Nov; 9(6):729-35. PubMed ID: 18490303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease: overall effects of agalsidase alfa treatment.
    Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
    Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
    Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
    Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
    Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G
    Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.
    Weidemann F; Breunig F; Beer M; Sandstede J; Turschner O; Voelker W; Ertl G; Knoll A; Wanner C; Strotmann JM
    Circulation; 2003 Sep; 108(11):1299-301. PubMed ID: 12952834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
    Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
    Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
    Sasa H; Nagao M; Kino K
    Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
    Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
    Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.